N Engl J Med

AHA 2024: Tirzepatide reduces heart failure risk in patients with obesity, HFpEF

November 20, 2024

Tirzepatide significantly reduces the risk of CV death or worsening heart failure and improves quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

The international, double-blind, randomized, placebo-controlled SUMMIT trial included 731 patients with HFpEF (EF ≥50%) and a BMI ≥30. Participants were randomized to receive either tirzepatide (≤15 mg SC weekly) or placebo for ≥52 weeks. The two primary end points were a composite of adjudicated death from CV causes or a worsening heart-failure event (assessed in a time-to-first-event analysis) and the change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better quality of life).

Key findings

• Fewer patients in the tirzepatide group experienced CV death or worsening heart failure compared with the placebo group: 9.9% vs. 15.3% (hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.41-0.95; P = 0.026).
• Worsening heart-failure events occurred in 8% of the tirzepatide group vs. 14.2% of the placebo group (HR, 0.54; 95% CI, 0.34 - 0.85).
• The tirzepatide group had a significantly higher mean change in the Kansas City Cardiomyopathy Questionnaire score compared with the placebo group: 19.5 vs. 12.7 (P < 0.001).

Source:

Packer M, et al; SUMMIT Trial Study Group. (2024, November 16). N Engl J Med. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. https://pubmed.ncbi.nlm.nih.gov/39555826/